Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	371.94B -16.0%
Revenue (ttm)	38.43B +6.0%
Net Income	10.39B +18.9%
EPS	1.57 +15.4%
Shares Out	n/a
PE Ratio	31.32
Forward PE	31.93
Dividend	0.23 (0.46%)
Ex-Dividend Date	Apr 29, 2026

Volume	2,021,748
Open	49.80
Previous Close	49.92
Day's Range	49.08 - 50.25
52-Week Range	43.02 - 80.95
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2025, HKG:1276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error